BioNTechs, Mixed

BioNTech's Mixed Signals: Upgraded Guidance, a Cost-Sharing Win, and a $205 Million FDA Voucher

Published on 11/20/2026 at 21:31 | Editorial boerse-global.de
BioNTech raised its 2026 revenue guidance midpoint to EUR 1.7-1.9 billion, shifted future R&D costs to Roche and Genentech, and bought a $205 million FDA fast-review voucher.
BioNTech's Mixed Signals: Upgraded Guidance, a Cost-Sharing Win, and a $205 Million FDA Voucher Illustration mit AI erstellt.

BioNTech has been pulling several levers at once — raising its full-year revenue outlook, offloading future research costs onto a partner, and paying up for regulatory speed — even as its shares continued to slide in a jittery market.

The Mainz-based biotech now expects 2026 revenue in a range of EUR 1.7 billion to EUR 1.9 billion, having lifted the midpoint of that forecast. The company left its guidance for adjusted research and development costs, as well as adjusted selling and administrative expenses, unchanged.

Third-Quarter Profit, Nine-Month Loss

For the third quarter of 2026, BioNTech posted revenue of EUR 1.29 billion and an IFRS net profit of EUR 184.5 million. The picture darkens over a longer horizon: across the first nine months of 2026, the company recorded an IFRS net loss of EUR 1.17 billion. The Deutsches Ärzteblatt attributed the red ink to heavy spending on cancer research combined with a weaker COVID-19 vaccine business.

Should investors sell immediately? Or is it worth buying BioNTech?

Roche and Genentech Take On the Tab

On the collaboration front, BioNTech has exercised an option in its partnership with Roche and Genentech. From January 1, 2027, the two companies are in principle to bear the future research and development costs for the program in question. The ongoing adjuvant pancreatic cancer study will proceed as planned.

$205 Million for a Faster FDA Lane

BioNTech also struck a deal with Scholar Rock to acquire a voucher granting expedited review by the U.S. Food and Drug Administration, at a cash purchase price of $205 million. The company intends to use the voucher for a future marketing application covering one of its advanced cancer drug candidates. The transaction is subject to customary conditions, including antitrust clearance in the United States.

Analysts Diverge on Price Targets

Sell-side views on the stock have been moving in opposite directions. JPMorgan's Jessica Fye reiterated a "Neutral" rating yesterday while nudging her price target up to $93 from $92. H.C. Wainwright had gone the other way on November 10, trimming its target to $110 from $130 but keeping a "Buy" recommendation.

Shares Under Pressure

The stock fell 2.26% yesterday, with the broader U.S. equity market also retreating — pressure that Associated Press linked to worries about AI-related shares. The decline carried into today's session, with BioNTech down another 1.5% at EUR 73.05.

Ad

BioNTech Stock: New Analysis - 20 November

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

Disclaimer...
en | US09075V1026 | BIONTECHS | boerse | 70541093 |